Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Director Sells $61,761.96 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN – Get Free Report) Director Rahul D. Ballal sold 3,237 shares of Enliven Therapeutics stock in a transaction that occurred on Monday, April 1st. The shares were sold at an average price of $19.08, for a total transaction of $61,761.96. Following the transaction, the director now directly owns 22,341 shares of […]

Related Keywords

Canada ,China ,Rahuld Ballal , ,Enliven Therapeutics Inc ,Ameritas Investment Partners Inc ,China Universal Asset Management Co ,Tower Research Capital ,Nasdaq ,Royal Bank ,Enliven Therapeutics ,Get Free Report ,Director Rahul ,Research Capital ,Investment Partners ,China Universal Asset Management ,Enliven Therapeutics Daily ,Nasdaq Elvn ,Elvn ,Medical ,Insider Trading ,Nsider Trades ,Stocks ,